Table 2.
Lumbar measurements with GAFCHROMIC EBT3 film with gamma analysis utilizing the dose criterion relative to the global maximum dose method
| Treatment Plan | Global γ‐analysis constraints w/ 10% threshold | Treatment Platform | ||||
|---|---|---|---|---|---|---|
| TomoTherapy | Vero | TrueBeam (Flattened) | TrueBeam (FFF) | CyberKnife | ||
| Plan A | 3%/3 mm | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 2%/2 mm | 100.0 | 99.7 | 97.9 | 100.0 | 100.0 | |
| 1%/1 mm | 81.3 | 61.8 | 77.6 | 84.3 | 95.4 | |
| Plan B | 3%/3 mm | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 2%/2 mm | 99.9 | 98.7 | 98.5 | 99.3 | 99.3 | |
| 1%/1 mm | 93.9 | 62.3 | 81.5 | 87.3 | 85.3 | |
| Plan C | 3%/3 mm | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 2%/2 mm | 99.9 | 98.7 | 98.5 | 98.9 | 99.8 | |
| 1%/1 mm | 93.0 | 65.2 | 86.3 | 85.0 | 75.4 | |
| Plan D | 3%/3 mm | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 2%/2 mm | 99.7 | 100.0 | 96.9 | 99.8 | 100.0 | |
| 1%1 mm | 87.3 | 87.5 | 89.1 | 90.5 | 90.4 | |